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ABSTRACT 
Objective: To determine the effects of Tualang Honey (TH) on bone mineral 
density (BMD) as assessed by dual energy X-ray absorptiometry (DEXA) scan 
when used as an adjunct to anastrazole among postmenopausal breast cancer 
patients.  
Methodology: Patients (n=33) were recruited from the Oncology Clinic, 
Hospital USM, Kelantan, Malaysia. The inclusion criteria included 
postmenopausal women with breast cancer stages I, II, or III, oestrogen 
receptor (ER) positive and/or progesterone receptor (PgR) positive. The 
patients were randomized to receive either anastrozole (1 mg) alone or 
anastrazole (1 mg) and TH (20 g) intervention group. Bone DEXA scan was 
conducted twice, at baseline (during the first visit) and six months later. 
Results: The T scores were significantly decreased when compared to the 
baseline for both femoral (−0.40 vs −0.50, p = 0.013) and the lumbar spine 
(−1.60 vs –1.70, p = 0.034), following six months of anastrozole alone 
treatment. On the other hand, there was no significant difference between the 
baseline and the T scores following six months of treatment for both femoral 
(0.35 vs. 0.50, p = 0.286) and the lumbar spine (−1.05 vs –0.95, p = 0.074) for 
the intervention group indicating that TH can ameliorate bone loss as a result 
of anastrazole use. Administration of anastrozole significantly reduced the 
median femoral BMD by 2.23% and median lumbar spinal BMD by 2.84% after 
six months.  
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However, in the intervention group, there was no significant change in term of 
both BMD and T score when compared to the baseline following six months 
which again indicate the potential of TH in ameliorating bone loss.                                                                    
 
 
Conclusions: TH has the potential to be used as an adjunct to prevent bone 
loss among postmenopausal breast cancer women treated with anastrozole.  
Keywords: Bone Loss, bone mineral density, anastrozole, Tualang honey 
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ABSTRAK  
Objektif: Untuk menentukan kesan TH terhadap kepadatan mineral tulang 
(BMD) dengan menggunakan imbasan tenaga dwi x-ray absorptiometry (DEXA) 
dalam pesakit kanser payu dara yang telah putus haid dan dirawat dengan 
anastrozole. 
Metodologi: 33 pesakit dari Klinik Onkologi, Hospital USM, Kubang Kerian, 
Kelantan, terlibat dalam kajian ini. Mereka merangkumi wanita putus haid yang 
menghidap penyakit kanser payu dara peringkat I, II, atau II, dengan reseptor 
oestrogen (ER) positif dan / atau reseptor progesteron (PgR) positif. Pesakit 
kemudiannya dimasukkan secara rawak ke sama ada kumpulan anastrozole 
sahaja (anastrozole 1mg)  atau kumpulan intervensi anastrozole (1mg) dan TH 
(20g). Imbasan kepadatan tulang dijalankan dalam semua pesakit pada lawatan 
pertama dan juga semasa lawatan selepas rawatan selama enam bulan.  
Keputusan: Dalam pesakit yang dirawat dengan anastrozole, skor T selepas 
enam bulan rawatan telah menurun dengan ketara berbanding dengan skor T 
pada garis dasar di tulang femur (−0.40 vs. −0.50, p = 0.013) dan tulang 
belakang lumbar (−1.60 vs. −1.70 , p = 0.034), manakala dalam pesakit yang 
dirawat dengan anastrozole dan TH, tidak ada perbezaan yang signifikan 
antara skor T asas dan skor T selepas enam bulan rawatan di tulang femur 
(0.35 vs. 0.50, p = 0.286) dan tulang belakang lumbar (−1.05 vs. −0.95, p = 
0.074).  
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Enam bulan rawatan anastrozole mengurangkan BMD median tulang femur 
sebanyak 2.23% dan median BMD tulang belakang lumbar sebanyak 
2.84%. Walau bagaimanapun, rawatan enam bulan dengan anastrozole dan TH 
tidak menunjukkan sebarang perubahan yang signifikan pada skor T dan BMD 
jika dibandingkan dengan nilai-nilai asas. 
 
Kesimpulan: TH mempunyai potensi untuk digunakan sebagai rawatan 
pencegahan kerapuhan tulang di pesakit kanser payu dara putus haid yang 
dirawat dengan anastrozole. 
Kata kunci: Kerapuhan tulang, anastrozole, madu Tualang 
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SECTION 1 
INTRODUCTION 
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SECTION 1 
INTRODUCTION AND LITERATURE REVIEW 
 
 Worldwide, breast cancer is the most common type of malignancy 
among women. Early detection of breast cancer can save lives and prolonged 
life expectancy. Recently, several new medications have been developed for 
breast cancer treatment, among which is anastrozole. Anastrozole is an 
aromatase inhibitor used in postmenopausal women who are hormone–positive 
(Buzdar et al., 2006). 
 However, in addition to its potential benefits, anastrazole causes several 
some side effects including bone loss (Forbes et al., 2008). Therefore, there is 
higher risk of osteoporosis, fall and fractures among its users. Bone loss tends 
to progress much more rapidly following menopause due to oestrogen 
deficiency. Decline serum oestradiol levels contribute to increase lifespan of the 
osteoclasts, leading to bone resorption while at the same time decreasing the 
lifespan of osteoblast. The overall effects are less bone is formed contributing to 
lower bone mineral density (BMD). 
 Bone strength and density are very closely related. For example, 
individuals with low BMD have increased risk for fragility fracture. Osteoporosis 
is the systemic skeletal disease characterized by low bone mass and 
microarchitectural deterioration of bone tissue, with a consequent increase in 
bone fragility and risk of fracture. In 1994, with the development of the DEXA 
units capable of highly precise and accurate measurement of the BMD 
(Bontranger).the World Health Organization (WHO) recommended the use of 
BMD for diagnosis of the osteoporosis. Osteoporosis in the postmenopausal 
women is defined as having a BMD more than 2.5 standard deviation (S.D) 
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below the mean T score. T score were determined according to the WHO 
definitions as SD unit from the mean BMD of 25 years old healthy women. 
Based on the WHO, the BMD classifications are operationally used to define 
patients as the below groups: 
1) Normal = T score of at least -1.0 
2) Osteopenia = -1< T score < -2.5 
3) Osteoporosis = T score ≤ - 2.5 
4) Established osteoporosis = T ≤ - 2.5 in the presence of one or more fragile 
fractures   
 
It is estimated that 80% of the worldwide population rely on the traditional 
medicine to meet their health care needs as alternative to the conventional 
medicine (Bogdanov et al., 2008). Among the traditional medicine, natural 
products including honey, has long been used for medicinal purposes in 
recorded history. Honey has been proven to be of value in accelerating wound 
healing, as well as ulcers and skin infection (Christiansen 1991). It also has 
shown to be effective antioxidant and anti-inflammatory agent. Honey consists 
of primary sugar such as monosaccarides, dissacharides, oligosaccarides and 
polysaccarides as well as enzymes such as glucose oxidase, diastase, 
invertase, catalase and peroxidase (Bogdanov et al., 2008). The other chemical 
contents of honey are organic acids, vitamins, amino acid, proteins, flavonoids 
and phenolic acid that are beneficial for human health (Christiansen 1991). 
 In Malaysia, TH has been widely used by the researchers in order to 
discover its hidden potential value. It is known to have antimicrobial, 
antiparasitic, antioxidant, and anti-inflammatory effects. Its content of high 
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antioxidant as well as exerting anti-inflammatory effect which can act as a free 
radical scavenger can reduce the oxidative stress level and inhibit the 
cytokines. All of these can result in survival of osteoblast, reduced 
osteoclatogenic activity and reduced bone loss (Mohd Effendy, 2012). 
 The objective of this study is to determine and compare bone density of 
the postmenopausal breast cancer patients treated with anastrazole alone and 
Anastrazole + TH supplementations for six months. 
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SECTION 2  
METHODOLOGY 
 
General objective:  
The aim of this study to determine the effect of TH on BMD (assessed by DEXA 
scan) in postmenopausal breast cancer patient treated with anastrozole. 
 
Specific objectives: 
1. To investigate the mean osteoporotic changes in pre and post treatment in 
postmenopausal breast cancer patient treated with Anastrazole (control group) 
and Anastrazole with TH Supplementation (intervention group). 
2. To compare the mean osteoporotic changes in six months duration between 
these two groups.  
3. To determine the effect of TH supplementations in preventing osteoporosis in 
postmenopausal breast cancer patient treated with anastrozole. 
 
Methodology: 
This is a randomized, prospective controlled trial for six months duration, which 
will be conducted in Radiology Clinic, Hospital USM, Kubang Kerian, Kelantan.  
 
Population and Sample: 
All postmenopausal women with breast cancer recruited during the study’s 
duration. 
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Sampling technique:  
Sampling using randomization based on block of four using computer generated 
programme will be applied.  
Randomization programme from (www.randomization.com). 
 
Inclusion Criteria: 
1. Postmenopausal women with breast cancer without bone metastasis 
receiving anastrozole as a treatment within a year. 
 
Exclusion Criteria: 
1. History of allergy to honey 
2. Receiving hormone replacement therapy 
3. Known bone metabolism disorder 
4. Previously diagnosed with osteoporosis, hip fracture or prosthesis 
5. Liver or renal dysfunction. 
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Sample Size Calculation: 
Sample size calculation to compare quality of life score between groups was 
done by comparing two means using Power and Sample size calculation 
software version 3.0.10. 
Input: 
n = 34 
The calculated sample size is 34 in each group; however after considering 25% 
drop out, the final sample size for each group is 42. The total of subject is 84. 
 
Research Tools 
a. Physical examination (height, body weight) 
b. Bone densitometry scan machine (DEXA SCAN , Hologic, Dynamic 2 
at Radiology Department, HUSM) 
 
Subjects 
 Subject will be screened against the inclusion/exclusion criteria. 
Subjects who agreed to participate will be asked to sign written 
 
power
standard deviation of bone density level was 1.0 (Based on Theresa 
A.Guise, The oncologist Journal) 
clinically significant difference between in bone density level between 
groups is set at 0.8 
m=ratio of control to intervention group is 1 
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informed consent forms. They will be informed to come again in 
the 2 weeks for the bone scan appointment. 
 Patient will be randomized based on blocks of 4 for two groups 
(Anastrozole group/ control group) and Anastrozole with TH 
(intervention group) using a computer generated programme. 
 Group 1 (control group: Subject receiving anastrozole 1 mg 
daily(po) 
 Group 2 (intervention group): Subject receiving anastrozole 1 mg 
daily and TH supplement of 20 gram daily. The choice of the dose 
of TH in this study is based on the study conducted by Nik Hazlina 
et al. (2012). 
 
Data collection 
 During visit 1 (baseline) for the postmenopausal breast cancer patient on 
anastrozole the baseline of serum biochemical marker and bone densitometry 
scan (DEXA) will be performed. Bone densitometry scan will be reported by 
radiologist, Dr. Nik Munirah Nik Mahdi or Prof Mohd Shafie bin Abdullah and 
radiology medical officer, Dr Nor Hasnina Mohd Hassan. 
 At visit 2 (month 6), repeated serum biochemical and bone densitometry 
scan (DEXA) will be performed. Patient will be informed about study completion 
and advised to continue normal routine follow up. Patients are allowed to 
withdraw from the study at any point of the study. 
 
 
8 
 
Compliance 
In order to ensure compliance of honey and anastrozole, subject will be 
educated regarding the importance of compliance to the supplement and 
anastrozole. Subjects will be given a diary and phone calls will be made every 
month to ensure compliance. TH was supplied every two months. 
 
Methodology of Bone Densitometry 
 Patients would undergo a bone densitometer examination using a 
standard imaging protocol and Hologic, Dynastic 2 bone scan at the 
Department of Radiology USM Kubang Kerian, Kelantan. The bone 
densitometry assessment has very low radiation dose, about 1/10 of normal 
CXR exposure. 
 Patients will be asked to lie on their back, on a padded table, in a 
comfortable position. The lumbar spine (lower back) and the hip are the skeletal 
sites and are usually examined by using the scan. The densitometer normally 
performs spine and femur scans in about 6 minutes and 3 minutes, respectively, 
with adequate spatial resolution (1.2 x 1.2 mm). Total body scan can between 
10 to 20 minutes. 
 After a routine scan, the T and Z scores will be measured for the total 
body, dual femur and AP spine. Densitometer graph will be plotted based on the 
BMD and patient’s age will be compared against the T and Z scores. The Z-
scores can be used to compare a measurement to a reference value. The Z-
score is the number of standard deviations away from the average value of the 
reference group. This reference group usually consists of people of the similar 
age and gender and sometimes race and weight are also included. 
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 The T-score is the relevant measure when screening for osteoporosis. It 
is the bone mineral density (BMD) at the site when compared to the young 
normal reference mean. It is a comparison of a patient's BMD to that of a 
healthy thirty-year-old. The US standard is to use data for a thirty-year-old of the 
same sex and ethnicity, but the WHO recommends using data for a thirty-year-
old white female in general. Values for thirty-year-olds are used in post-
menopausal women and men over age 50 because they better predict risk of 
future fracture. The criteria of the WHO 2005 are: 
• Normal is a T-score of -1.0 or higher 
• Osteopenia is defined as between -1.0 and -2.5 
• Osteoporosis is defined as -2.5 or lower, (BD that is 2.5 standard 
deviations below the mean of a thirty-year-old man/woman) 
       Established osteoporosis = T ≤ -2.5 in the presence of one or more 
fragile fractures   
 
The bone densitometer images and data will be analysed by a radiologist. Data 
will be entered and analyzed using SPSS version 20 and p < 0.05 will be 
considered as statistically significant. The confidence interval will be set at 95%. 
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INTRODUCTION 
 Breast cancer is the most common malignancy affecting women in both 
developed and the less developing world. In 2011, it is estimated that more than 
508 000 women died due to breast cancer worldwide (World Health 
Organization, 2013). In Malaysia, the National Cancer Registry (2003-2005) 
reported an age-standardized rate of 47.3 per 100 000 women for breast cancer 
(Lim et al., 2008). Since advanced breast cancer in postmenopausal women 
remains an incurable disease its treatment is aimed at palliation and improved 
quality of life, inhibition of disease progression as well as improvement in 
survival time where possible. 
 Endocrine therapy for breast cancer is now a widely accepted treatment 
modality and is primarily directed at reducing the synthesis of oestrogen or 
alternatively blocking oestrogen receptors in tumours that are hormone-
sensitive. Anastrozole is a nonsteroidal oral aromatase inhibiting drug approved 
for use in postmenopausal woman with localized breast cancer (Howell et al., 
2005, Buzdar et al., 2006). It has been reported that five years of anastrozole 
administration is superior to tamoxifen if administered for the same duration and 
therefore, anastrozole has become the most commonly prescribed adjuvant 
endocrine therapy for hormone-dependent early breast cancer in 
postmenopausal women (Baum et al., 2003, Dowsett et al., 2010, Thurlimann et 
al., 2005). Nevertheless, in addition to its potential benefits, anastrozole known 
to cause bone loss (Forbes et al., 2008). 
 In women, bone loss progresses much more rapid following menopause 
due to oestrogen deficiency. Oestrogen is known to play a central role in the 
maintenance of normal BMD in women (Leslie et al., 1995). In postmenopausal 
12 
 
women, low oestradiol levels are associated with increased bone turnover, low 
BMD, and an increased risk of fracture (Chapurlat et al., 2000, Chapurlat et al., 
2001, Cummings et al., 1998, Ettinger et al., 1998, Garnero et al., 2000, Rogers 
et al., 2002). In the 10 years following the menopause, there is a reduction in 
BMD averaging 2% per annum (World Health Organization, 1994) with 
osteoporosis being the major cause of morbidity in postmenopausal women. 
Anastrozole markedly suppresses oestrogen levels and due to its mode of 
action, has the potential to have a deleterious effect on the skeletal health of 
postmenopausal women receiving the drug as adjuvant treatment for early 
breast cancer. 
 BMD measurements are important in evaluating patients at risk of 
osteoporosis (Kanis and Gluer, 2000). In general, the preferred method of 
testing is to use DEXA scans of the central skeleton to measure BMD of the 
lumbar spine and hip. In fact, the WHO working group recommended that the 
diagnosis of osteoporosis should be based only on the T-score obtained at the 
hip measured by DEXA. Therefore, BMD measurements in postmenopausal 
women should be interpreted using the WHO T‐score definitions of 
osteoporosis and osteopenia (Table 1) (Kanis and Gluer, 2000). 
 One of the strategy used for osteoporosis treatment is calcium 
supplementation (Mackerras and Lumley, 1997). Other alternative treatments 
use natural products. For example, polyphenols in fruits and vegetables have 
demonstrated beneficial effects on bone in rats (Muhlbauer et al., 2002, 
Devareddy et al., 2008). Natural antioxidants such as palm tocotrienols, have 
been shown to prevent bone loss in many osteoporosis-induced rat models 
(Ahmad et al., 2005).  
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Honey is a natural product that has been widely used for its therapeutic 
effects due to its antioxidant effect. Honey is composed primarily of fructose and 
glucose but also contains fructo-oligosaccharides (Chow, 2002) and many 
amino acids, vitamins, minerals and enzymes. The composition of honey varies 
depending on the plants on which the bee feeds. However, almost all natural 
honey contains flavonoids, phenolic acids, ascorbic acid, tocopherols, catalase, 
superoxide dismutase, reduced glutathione, some Millard reaction products and 
peptides. Most of the compounds act together synergistically (Johnston et al., 
2005, Rakha et al., 2008).  
 TH (Koompasia excelsea) is a multifloral honey collected in the jungles of 
Malaysia and in many other Asian countries. It is traditionally used as a health 
and anti-ageing supplement. A study on its antioxidative compounds reported 
that TH had the highest total phenolic, protein and ascorbic acid content when 
compared to other honey types in Malaysia (Kishore et al., 2011). In addition, 
TH had also shown the highest radical scavenging activity, suggesting that it is 
a good source of antioxidant able of free radical scavenging which can help 
reduce bone resorption activity by osteoclasts and subsequently maintaining 
overall bone health. 
 Therefore, the objective of this study is to determine and compare BMD 
of postmenopausal breast cancer patients, treated with anastrozole alone or 
anastrozole plus TH supplementation for six months. 
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METHODOLOGY 
 The aim of this study was to determine the effect of TH on BMD 
(assessed by DEXA scan) in postmenopausal breast cancer patient treated with 
anastrozole. Specifically, it was to investigate the mean osteoporotic changes in 
pre and post treatment in postmenopausal breast cancer patient treated with 
anastrozole (control group) and anastrozole with TH Supplementation 
(intervention group). Besides, the mean osteoporotic change in six months 
duration between was also compared between the two groups.  
 This study was a randomized, prospective controlled trial for six months 
conducted in Radiology Clinic, Hospital Universiti Sains Malaysia, Kubang 
Kerian, Kelantan between March 2015 and April 2016. The ethical approval was 
obtained from Human Research Ethics Committee of Universiti Sains Malaysia 
Research Ethics Committee of Universiti Sains Malaysia (JEPem USM Code 
USMKK/PPP/JEPeM/[260.3(210)] which complies with the Declaration of 
Helsinki.  
By using the two means formula, sample size with power of 90%, alpha 
0.05, difference of interest of 0.8, and S.D of 1.0, a total of 34 patients was 
recruited for both groups. The inclusion criteria were postmenopausal women 
with breast cancer without bone metastasis receiving anastrozole as a 
treatment within a year. Patient with history of allergy to honey, receiving 
hormone replacement therapy, known bone metabolism disorder, previously 
diagnosed with osteoporosis, hip fracture or prosthesis and liver or renal 
dysfunction were excluded from this study.  
 Recruited patients were then assigned into either control group or 
intervention group using randomization based on block of 4 by a computer 
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generated programme. The patient in control group received anastrozole (1 mg) 
daily, while the patient in group 2 received Anastrozole (1 mg) daily and TH 
supplement (20 g) daily. The choice of the dose of TH in this study is based on 
the study conducted by Nik Hazlina et al.(2012). 
 After obtaining written informed consents from the patients, bone 
densitometry scan (DEXA) was performed at the first visit. Patients underwent a 
bone densitometer examination using a standard imaging protocol and Hologic, 
Dynastic 2 bone scan at the Department of Radiology USM Kubang Kerian, 
Kelantan. The bone densitometry assessment has very low radiation dose, 
about 1/10 of normal CXR exposure. 
Patients were asked to lie on their backs on a padded table, in a 
comfortable position. The lumbar spine (lower back) and the hip are the skeletal 
sites and are usually examined by using the scan. The densitometer performed 
spine and femur scans for approximately 6 and 3 minutes respectively, with 
adequate spatial resolution (1.2 x 1.2 mm). For the total body scan, the time 
was approximately 10 to 20 minutes. Following a routine scan, the T and Z 
scores were measured for the total body, dual femur and AP spine. 
Densitometer graph was plotted based on the BMD and patient’s age was 
compared against the T and Z scores. 
 After six months of treatment at second visit, repeated measurements of 
serum biochemical and bone densitometry scan (DEXA) were performed. 
Patient was informed about study completion and advised to continue normal 
routine follow up. Patients were also allowed to withdraw from the study at any 
time during the study duration. 
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 Quantitative data were analyzed using Microsoft® Office Excel and 
Statistical Product and Service Solutions (SPSS) for Windows, SPSS Inc.© 
(version 18, SPSS Inc., Chicago, IL,USA). Continuous variables are expressed 
as mean ± S.D or median (interquartile range, IQR) and categorical variables as 
percentages. The student’s and paired-sample t-tests were performed if 
normality was demonstrated by histogram. Otherwise, non-parametric tests 
(Mann-Whitney U or Wilcoxon signed rank tests) were used. Pearson chi-
square test and Fisher’s exact test were used to compare the categorical 
variables. All statistical tests were considered significant when the two-sided p 
value was < 0.05.  
 
RESULTS 
Patients 
 In this randomized control trial study, 40 postmenopausal breast cancer 
patients were screened and were found to be eligible for the study. They were 
then randomized into two treatment groups, i.e. anastrozole and anastrozole + 
TH. However seven patients withdrew from the study (two due to 
noncompliance to honey, three refused to continue with the study, a patient was 
found unsuitable due to osteoporotic fracture which occurred during the study 
and a patient unfortunately passed away) (Table 2).  
Finally, a total of 33 patients was recruited and among them 13 patients 
received anastrozole treatment and the remaining 20 patients received 
anastrozole together with TH supplementations during the six months study 
period. At the time baseline DEXA scan was done, the patient’s age ranged 
between 41 and 76 with a mean age of 58 years. The postmenopausal breast 
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cancer patients had a mean menopause age of 49 years. They were diagnosed 
with breast cancer stages I to III and with the majority (54%) suffering from on 
stage II disease. The mean body mass index (BMI) of the patients was 28.0 
kg/m2 which is considered to be in the overweight range.  
 
The effects of Treatment on T-score and BMD 
 Table 3 demonstrated the results of the T score at baseline and six 
months after treatment for both anastrozole and anastrozole + TH treatment 
groups. In the patients treated with anastrozole, the baseline median T score of 
femoral and lumbar spine were −0.40 and −0.60 respectively. The Wilcoxon 
Signed-ranks test indicated that the T scores after six months of treatment were 
significantly decreased compared to the baseline scores at both femoral (−0.40 
vs. − 0.50, p = 0.013) and lumbar spine (−1.60 vs. –1.70, p = 0.034). TH 
supplement significantly demonstrated protective effect against bone loss 
following anastrozole treatment. In patients treated with anastrozole and TH 
supplement, there was no significant difference between the baseline T scores 
and the T scores after six months of treatment at both femoral (0.35 vs. 0.50, p 
= 0.286) and lumbar spine (− 1.05 vs. – 0.95, p = 0.074).  
 Table 4 showed the result of the BMD at baseline and six months after 
treatment for both groups. The baseline median BMD of the study patients in 
anastrozole group was 0.808 g/cm2 at femur and the mean BMD at the lumbar 
spine was 0.811 g/cm2. In comparing the BMD of femur before and after 
anastrozole treatment, there was significant decrease of BMD at six months 
when compared with the baseline value after analysis with Wilcoxon Signed 
Rank test (0.808 g/cm2 vs. 0.70 g/cm2, p = 0.001). For measurement at lumbar 
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spine, the BMD also significantly decreased after six months of anastrozole 
treatment, analyzed with paired t test (0.811 g/cm2 vs. 0.788 g/cm2, p = 0.006). 
For patients in anastrozole + TH treatment group, the baseline median BMD 
was 0.901 g/cm2 at femur and the mean BMD at the lumbar spine was 0.893 
g/cm2. There were no significant changes seen in the bone density between the 
baseline and after six months of treatment at both femoral (0.901 g/cm2 vs. 
0.914 g/cm2, p = 0.100) and lumbar spine (0.893 g/cm2 vs. 0.897 g/cm2, p = 
0.346).  
 
DISCUSSION 
 The evolution of adjuvant endocrine treatment increased the survival 
rates of postmenopausal hormone-related early breast cancer patients. The 
emergence of anastrozole has changed the initial treatment strategy with the 
previous gold standard of Tamoxifen. Anastrozole has been demonstrated to 
have higher efficacy than Tamoxifen in ER-dependent breast tumors' 
pharmacological strategies. However, as accelerated bone loss is associated 
with oestrogen deficiency, the most common complication of anastrozole 
treatment is aromatase inhibitor-associated bone loss. Osteoporosis can be 
developed and is amplified by age-related lack of oestrogens, which increases 
the risk of vertebral and hip fractures. There is a study found that anastrozole 
was associated with a greater fracture incidence than Tamoxifen (11% versus 
7.7%, respectively) (Baum et al., 2003).  
 This randomized controlled trial was conducted to evaluate the protective 
effect of TH on bone loss caused by anastrozole treatment in postmenopausal 
breast cancer women. The mean BMD measurement at baseline for the study 
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patients was 0.85 g/cm2 at the femoral and the BMD at the spine was 0.86 
g/cm2, while the measured mean femoral T score was −0.048 and the mean T 
score at the lumbar was −1.19. Most of the women were with normal BMD and 
T score at the baseline before treatment and only some of them were 
osteopenic.  
 The result at six months of treatment with anastrozole showed significant 
change in term of both T score and BMD when compared to the baseline levels. 
Six months of anastrozole significantly reduced median femoral BMD by 2.23% 
and median lumbar spinal BMD by 2.84%. Our findings are in accordance with 
the findings from previous studies on the effect of anastrozole to bone loss. 
Eastell et al. (2008) demonstrated in their study that anastrozole is associated 
with accelerated bone loss over the 5-year treatment period in 57 
postmenopausal breast cancer women. Inoue et al. (2015) also found in their 
study that in patients treated with anastrozole, the BMD of lumbar spine 
decreased by 4.3% from baseline at month 24 (p < 0.0001). Anastrozole 
treatment-related bone loss did not continue into the off-treatment follow-up 
period. Eastell et al.(2010) found that the recovery in lumbar spine BMD and 
absence of further loss at the hip is consistent with the reduction in the annual 
rate of fracture observed after treatment cessation in the main ATAC trial. 
 The mechanism of action of the anastrozole is to block the peripheral 
conversion (aromatization) of oestrogen from androgen precursors, effectively 
lowering tissue and circulating oestrogen levels (Winer et al., 2005, Osborne 
and Tripathy, 2005). Oestrogen has been shown to regulate bone remodeling 
by stimulating the expression of anti-resorptive factors such as osteoprotegerin. 
Oestrogen deprivation increases bone turnover and osteoclast activity, causing 
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bone resorption and formation to become unbalanced (Riggs et al., 2002). This 
imbalance results in net bone loss as well as decreased bone quality. Such 
bone loss can lead to osteoporosis, which is associated with an increased 
fracture risk, decreased bone strength, diminished quality of life, and increased 
mortality (Higano, 2003, Hoff and Gagel, 2005, Higano, 2004). Therefore, the 
prevention of bone loss is important for postmenopausal women breast cancer 
women treated with anastrozole in order to preclude a fracture. 
 Over the past few years, TH has been shown to exhibit protective effects 
on bone. Study performed by Zaid et al. (2010) has shown that daily 
consumption of TH for two weeks in female ovariectomized rats was able to 
promote an increase in bone density. Our study investigated the protective 
effect of TH on bone in postmenopausal breast cancer women treated with 
anastrozole and the result at six months of combined anastrozole and TH 
treatment showed no significant change in term of both BMD and T score when 
compared to baseline values. Our data demonstrated that the TH could control 
BMD at both femur and lumbar spine from decreasing due to effect of 
anastrozole treatment. 
 The protective effect on bone is probably due to the antioxidants found in 
honey such as flavonoids and phenolic acids (Jaganathan and Mandal, 2009, 
Buratti et al., 2007). The main phenolic and flavonoid compounds in TH include 
kaempferol, quercetin, ellagic acid, gallic acid, hesperetin, and catechin 
(Hussein et al., 2011). Previous studies reported that flavonoids mainly 
quercetin and kaempferol exert a potent inhibitory effect on osteoclastic bone 
resorption and apoptosis in a rabbit long bone osteoclast model (Wattel et al., 
2003). They are also involved in inhibition of NF-κB and activator protein-1, a 
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transcription factor highly related to osteoclastic differentiation (Wattel et al., 
2004). Flavonoids may also inhibit RANKL-induced formation of multinucleated 
osteoclasts and expression of osteoclastic differentiation markers; RANK and 
osteocalcin receptor (Pang et al., 2006). Flavonoids have been shown to inhibit 
production of nitric oxide and expression of inducible nitric oxide synthase 
(iNOS) (Gonzalez-Gallego et al., 2007) which will result in inhibition of 
osteoclast activity. These protective mechanisms of flavonoids on bone strongly 
indicate that it can be considered as protective agent against bone loss. The 
positive effects of TH on bone are probably due to its anti-oxidative property. 
Apart from that, it may due to its anti-inflammatory (Al-Waili and Boni, 2003, 
Owoyele et al., 2011) and anti-osteoporotic properties (Farid, 2009). 
Our study demonstrated that combined treatment of anastrozole with TH did not 
significantly decrease BMD and T scores at both femur and lumbar spine after 
six months. Thus, TH has the potential to be used as a preventive agent against 
bone loss in postmenopausal breast cancer women treated with anastrozole.  
The main limitation of this study is the difficulty in recruiting expected sample 
size due to time, non probability sample of convenient, financial constraints and 
longevity of the study. Even though the recruited sample size was smaller than 
the expected size, this study still managed to produce significant outcomes from 
the statistical analysis. However, due to limited small sample size, the study 
was under-powered ( power of study is 0.58 ),  so the result cannot be applied 
to the general population.  Another limitation was that the measurements and 
intervention were made without blinding of the researcher to the experimental 
group, which has potential for bias. However, potential bias was minimized by 
22 
 
random assignment of participant and following standardized protocol by 
investigator.  
Thus, a larger and multi-centered randomized controlled trial should be 
conducted in future to further explore the mechanism of TH on overall bone 
metabolism and its side effects.  
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